Challenges Addressed: The refined version of the Ethics-Based Genetic Decision Application solves issues like unequal access, privacy vulnerabilities, and ethical concerns in genetic testing by prioritizing transparency and fairness. It provides actionable insights for patients and healthcare providers, addressing the need for privacy, equity, and informed decision-making. As the tool advances, there is a plan in place to integrate Polygenic Risk Scores (PRS) to enhance personalized insights. PRS evaluates the cumulative effect of multiple genetic variants, offering a more nuanced understanding of risks for complex diseases like diabetes, cancer, and cardiovascular conditions. This integration will allow EGDA to provide more precise recommendations, balancing medical utility with ethical considerations. Future advancements will focus on addressing PRS limitations, such as data disparities across ethnic groups and the challenge of interpreting probabilistic risk information, ensuring equitable and accurate assessments for all users.

Broader impact: Orional aspects of data privacy, ethical concerns, and affordability all remain staples to the finalizations of the web-based site, instead of prioritizing clinical utility like most genetic tools do. The benefits of a smaller application enable nuanced, patient-specific advice, directly addressing their unique financial, ethical, and health priorities. Additionally, one of the main objectives of the tool was to ensure an ethically sound input and output, meaning that the whole process of taking the test and conversing with the chatbot prioritizes transparency, privacy, and equitable practices in a smaller, tightly managed user base, ensuring that every decision aligns with core bioethical principles. Specifically, principles that align with the patient's form results.

Logistics: The site is currently built through Wix for ease of use and customizability as well as a lack of manual coding. The chatbot attached to the site is built through Zapier and given information about genetic diseases as well as genetic testing to answer questions with prior information. The chatbot uses generative AI as well as advanced machine learning to take the scripts and shape them into concise responses for concerned patients. Created through type form, the form on the other hand helps tailor personalized recommendations for genetic testing based on the patient’s financial, ethical, and privacy needs. This focused approach simplifies decision-making, providing clear next steps and resources, while ensuring the patient’s unique preferences are respected.

Case Study: Anna, who is concerned she might be a carrier for on the website after hours of research, where she hasn't had much luck. The information on genetic diseases is often confusing and she isn't sure if she should pay the fee to see a genetic counselor's user-friendly interface.

Taking the Form
She decides to take the form to better understand her current situation as well as outline her preferred outcomes and ethical preferences. The form asks her tailored questions about:

• Her specific genetic concerns (e.g., BRCA testing).
• Comfort with data storage and sharing practices.
• Preferences for affordable or insurance-covered options.
• Willingness to discuss the results with her family.
• The desire for counseling or further support.
• The questions are straightforward and designed to capture her unique values, priorities, and needs. Immediate Feedback
  After completing the form, Anna receives a personalized summary outlining: Affordable testing providers that meet her privacy and data-sharing preferences, information on genetic counselors in her area who specialize in family-centered care, and a breakdown of insurance coverage options, along with out-of-pocket cost estimates.

Engaging with the Chatbot: To clarify her next steps and answer any remaining questions, Anna uses the integrated chatbot. She types: “Will my genetic data be shared with third parties?”
The chatbot responds with detailed, context-specific information:
EX. “Based on your preferences, here are testing providers that explicitly prohibit third-party data sharing. Would you like to explore these options further or connect with a counselor for personalized guidance?” The chatbot quickly replies to her questions with well-thought-out and concise answers. Connecting with a Counselor if Necessary: Feeling reassured, Anna uses the scheduling feature recommended by the chatbot to book a session with a certified genetic counselor at the most affordable price for her. The counselor specializes in interpreting BRCA-related risks and addressing ethical concerns like family discussions and future planning.

Unconventionally Advancing Healthcare: prioritizing patient input in genetic testing decisions is a large part of this application as well as minimizing counselor biases, and focusing on equity. It simplifies complex ethical considerations into clear, personalized steps that reflect patient values. By centering privacy, affordability, and autonomy, the tool redefines healthcare decision-making and bridges the gap between cutting-edge genetics and ethical accountability, fostering greater trust and accessibility.

• Price Transparency: It evaluates testing options based on the user’s budget, identifying affordable choices and highlighting insurance-covered options. This ensures patients can make cost-conscious decisions without compromising on quality.
• Affordability: By categorizing tests according to personal financial feasibility, the tool reduces barriers to access, particularly for underrepresented groups, making genetic testing more equitable.
• Patient Autonomy: The tool empowers patients to prioritize their preferences, such as privacy or data-sharing, guiding them through ethical and financial considerations in a way that aligns with their personal values, something not every doctor can do.

Challenges in Genetic Testing and the Role of Polygenic Risk Scores

Genetic testing holds incredible promise, but its risks can outweigh the benefits without ethical guidance. What happens when the lines between genetic transparency and success are blurred? What tools need to be in place for genetic testing to succeed?

Genetic testing tools, despite their promise, still face several limitations and challenges. Inaccuracy is a common issue, with tests sometimes showing false positives or negatives, leading to unnecessary anxiety or missed diagnoses. Their predictive power is also limited, particularly for complex diseases influenced by multiple genes and environmental factors, where genetic tests often don’t provide a full picture of risk. Additionally, many direct genetic tests lack proper regulation, and testing methods can vary in quality.

Ethical concerns also arise, especially around privacy, as genetic data can be misused or exposed in data breaches. There are also concerns about the accessibility and equity of genetic testing, with tests often being costly and based on data from limited populations, making them less accurate for underrepresented groups. Although Genetic tests are included in American healthcare, their accessibility, coverage, and availability can vary significantly depending on the type of test, the healthcare provider, and insurance policies (for example, if your insurance type doesn’t cover genetic testing, you may have to pay out of pocket for it). Lastly, the emotional impact of testing can be significant, with many individuals facing stress or anxiety over uncertain or untreatable conditions. Despite its potential, genetic testing needs further refinement and ethical oversight to ensure accurate use. Here is where PRS comes in. A polygenic risk score (PRS) is a tool used to estimate an individual’s likelihood of developing certain complex diseases based on the effect of many genetic variants. Unlike traditional genetic tests that focus on single gene mutations, PRS assesses thousands of small genetic contributions across the genome to predict the risk for conditions like heart disease, diabetes, and cancer. While PRS represents a significant advancement in personalized medicine, offering new insights into disease susceptibility, it also comes with challenges.

Complex Diseases: PRS are used to predict the risk of diseases like diabetes, heart disease, or cancer, which are influenced by many genes and environmental factors. However, these scores are not definitive because they only assess genetic contributions, often without accounting for lifestyle or environmental factors. Clarity: Even when a PRS indicates a high genetic risk, it doesn’t guarantee that a person will develop the condition. Conversely, a low-risk score doesn’t rule out the possibility of developing the disease, nor will it give the patient any hard clarity on whether or not they are a candidate for what they are being tested for. Ethnic Distinction: PRS are typically based on data from people of European descent, making them less accurate for individuals from other ethnic groups. This limitation raises concerns about fairness and equity in genetic risk assessments. Risk: PRS can generate anxiety or confusion, as individuals may not know how to act on information about slightly elevated risks for multiple conditions.

Imagine, if despite all of this there was a tool that was able to sufficiently break down the ethical risks of genetic tests as well as allow genetic testing to be accessible to everyone. The Ethics-Based Genetic Testing Decision Tool or Ethical Genetic Decision Guide (EGDG). is a framework designed to guide ethical decision-making in the use of genetic tests. It helps healthcare professionals, patients, and policymakers assess whether a genetic test is appropriate by weighing various ethical considerations, such as patient autonomy, informed consent, potential harm, privacy, and fairness. The tool also factors in the test’s medical necessity, accuracy, and potential societal impact. By providing a well-thought-out approach to evaluating genetic testing options, it aims to ensure that decisions are made responsibly and ethically in line with both medical benefits and ethical principles.

Each new genetic test that is developed raises serious issues for medicine, public health, and social policy regarding the circumstances under which the test should be used, how the test is implemented, and what uses are made of its results. Should people be allowed to choose or refuse the test, or should it be mandatory, as newborn screening is in some states? Should people be able to control access to the results of their tests? If test results are released to third parties such as employers or insurers, what protections should be in place to ensure that people are not treated unfairly because of their genotype?

Genetic counselors play a critical role in helping individuals understand and navigate the complexities of genetic testing. They assess family history, explain the risks and benefits of testing, interpret results, and provide support in making informed medical decisions. The EGDG will help ensure informed consent from all parties and allow counselors to provide personalized recommendations that consider both medical and ethical factors. By guiding patients more effectively, the tool enables counselors to manage complex cases better and improve the overall quality of genetic testing decisions.

The Ethical Genetic Decision Guide is an innovative product that is worth the investment because it helps ensure that genetic testing is done ethically and responsibly. It protects patient rights and privacy while giving genetic counselors a clear way to handle tough ethical situations. This tool improves care, reduces the risk of mistakes, and ensures patients make informed decisions. It also promotes fairness by addressing issues like unequal access to testing. It builds trust in genetic testing and healthcare, making it valuable for better patient care and ethical practices.

Rule-Based Component: The tool uses predefined ethical rules aligned with established bioethical principles, including autonomy, non-maleficence, beneficence, and justice. These rules form a base layer that provides consistent, structured responses, such as flagging concerns around informed consent or patient privacy. Data is drawn from genetic databases and genetic counseling models to better ensure patient satisfaction as well as data transparency between customer and provider.

Data inputs and outputs:

Micro FlowChart 2024

Inputs: Patient demographics, family medical history, test type, clinical context, and individual patient values (e.g., preferences regarding data privacy, desire for preventive health insights).

Outputs: Ethical risk assessment, decision recommendations (e.g., proceed, reassess, delay), and structured guidance for counselors to navigate specific ethical concerns.

Risk-Benefit Analysis and Ethical Rule Checks: An algorithm could assess potential benefits and risks associated with the genetic test based on its predictive accuracy and possible outcomes. A scoring system might compare the potential medical benefit (like early intervention) against risks (like emotional distress or privacy concerns) to produce an overall score for each patient. Note that all decisions and reassessments will be provided in the correlation between the genetic counselor and the consenting patient.

AI-Driven Component: An AI model based on machine learning assesses more nuanced ethical concerns that vary case-by-case, like patient-specific risk sensitivity or socio-demographic equity in test access. The AI learns from past decisions, trends in genetic counseling data, and input parameters, helping refine ethical predictions and identifying potential red flags.

Feasibility: The feasibility of implementing the EGDG depends on several factors, particularly the training requirements for healthcare professionals and genetic counselors. To effectively use the tool, a structured training program would likely be needed to help users navigate its interface, understand the ethical scoring system, and interpret results. Adoption time may vary, but with a well-designed, user-friendly interface, initial onboarding could take a few weeks, followed by periodic training to address updates. For genetic counselors, using the EGDG efficiently in practice may initially extend consultation times, though, with experience, they could incorporate it smoothly into their workflow, improving decision quality and patient support.

The EGDG tool stands to revolutionize the future of personalized medicine and shape genetic testing policies by weaving ethical accountability into every test and every decision. Its algorithmic framework doesn’t just assess genetic risk; it actively balances risks, benefits, and the deeply personal values that define each patient’s journey. With a clear, AI-driven analysis of privacy, equity, and autonomy, the tool offers genetic counselors and healthcare professionals a way to navigate complex decisions confidently and compassionately.

By embedding these ethical checks within a precise, technical structure, EGDG has the power to make genetic testing more accessible, transparent, and equitable. This shifts the paradigm from merely scientific accuracy to a holistic approach that respects individual rights and societal standards alike. In doing so, the EGDG is setting a standard for the next era of healthcare: one where technology not only advances clinical practice but profoundly respects the humanity it’s designed to serve.

Bioethics is a quickly developing field and a necessary factor when developing all sorts of novel technologies…Thank you for reading.

Works Cited

American Health Organization. www.ama-assn.org/search?search=medical+ethics.

American Journal of Bioethics. www.tandfonline.com/doi/full/10.1080/15265161.2024.2377118#abstract.

OpenAI. ChatGPT, Version 4, OpenAI, 2024. CD-ROM.

Cooke Bailey, Jessica N., et al. “Diversity in Polygenic Risk of Primary Open-Angle Glaucoma.” Genes, vol. 14, no. 1, 30 Dec. 2022, p. 111, pmc.ncbi.nlm.nih.gov/articles/PMC9859496/, https://doi.org/10.3390/genes14010111. Accessed 17 Oct. 2024.